Following correspondence with Health Canada and Santhera, we present the results of the negotiated agreement: Santhera formally commits to offering, and thus delivering, Catena to Canadian patients who are approved by Health Canada’s Special Access Programme (SAP). The price will remain about the same. Santhera can in no way influence...
February 27, 2013: Santhera Pharmaceuticals announced the voluntary withdrawal of Catena® from the Canadian market. This decision follows review of additional data from clinical trials in patients with Friedreich’s Ataxia, and subsequent consultation with Health Canada.
Press Release Liestal, Switzerland, May 20, 2010 – Santhera Pharmaceuticals (SIX: SANN) announced today that its MICONOS Phase III study evaluating Catena®/Sovrima® for the treatment of Friedreich’s Ataxia missed its primary endpoint. Trends towards improvement in the key neurological endpoint were however identified by a meta-analysis of all Santhera’s Phase...
Some relevant information about Catena® (Idebenon) Catena®: Fact Sheet Catena®(idebenone): Product Monograph Catena®(idebenone): Product Monograph. Part III Actual Payer Coverage in Canada for CATENA® (Idebenon) Santhera Pharmaceuticals about preliminary results of the CATENA US clinical trial
News Release Liestal, Switzerland, July 24, 2008 – Santhera Pharmaceuticals (SWX:SANN), a Swiss specialty pharmaceutical company focused on neuromuscular diseases, announced today that Health Canada has approved with conditions SNT-MC17/idebenone for the treatment of Friedreich’s Ataxia. Health Canada’s decision is the first marketing authorization worldwide for any Friedreich’s Ataxia therapy....
Following correspondence with Health Canada and Santhera, we present the results of the negotiated agreement: Santhera formally commits to offering, and thus delivering, Catena to Canadian patients who are approved by Health Canada’s Special Access Programme (SAP). The price will remain about the same. 2. Santhera can in no way...
Santhera Pharmaceuticals announced the voluntary withdrawal of Catena® from the Canadian market. This decision follows review of additional data from clinical trials in patients with Friedreich’s Ataxia, and subsequent consultation with Health Canada. You can read the entire press release on Santhera’s website.
